Global Antimicrobial Resistance Market Report

Global Antimicrobial Resistance Market is poised to witness substantial growth, reaching a value of USD 11.73 Billion by the year 2033, up from USD 5.94 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 7.86% between 2025 and 2033.

Antimicrobial Resistance Market Size and Forecast to 2033

The burgeoning threat of antimicrobial resistance (AMR) continues to drive significant market interest. This critical global health challenge necessitates the development of novel therapeutic solutions and diagnostic tools. The escalating incidence of drug-resistant infections, coupled with the increasing burden on healthcare systems worldwide, underscores the urgent demand for effective interventions. Furthermore, heightened public awareness campaigns and initiatives by international health organizations are contributing to a more proactive approach in tackling AMR. This collective focus on mitigation and treatment strategies is propelling innovation and investment within the antimicrobial resistance market, fostering a robust environment for research and development activities aimed at combating this pervasive threat.

Market Dynamics

Antimicrobial Resistance Market Drivers

• Increasing Prevalence of Antimicrobial-Resistant Infections: The global rise in infections caused by drug-resistant microorganisms is a paramount driver for the antimicrobial resistance market. Data from the Centers for Disease Control and Prevention (CDC) indicates that more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, resulting in over 35,000 deaths. This escalating public health crisis necessitates continuous investment in novel antimicrobial agents and diagnostic tools to effectively combat these resilient pathogens. The World Health Organization (WHO) also highlights the alarming spread of multi-drug resistant bacteria, including extensively drug-resistant tuberculosis, emphasizing the urgent need for new treatments and surveillance systems to track and contain these threats. The economic burden associated with prolonged hospital stays and treatment failures due to AMR further incentivizes market growth, as healthcare systems seek solutions to mitigate these costs.
• Growing Research and Development Initiatives: Significant investments by government agencies and private organizations into antimicrobial resistance research and development are propelling market expansion. The Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services agency, has consistently funded the development of new antibiotics and countermeasures against antibiotic-resistant bacteria. Similarly, the European Commission, through various programs, supports collaborative research projects aimed at discovering and developing novel antimicrobial compounds. These initiatives often include grants, incentives for pharmaceutical companies, and partnerships between public and private entities to accelerate the discovery of new drug candidates and diagnostic technologies. This concerted effort to overcome the scientific and financial hurdles associated with antibiotic development is critical for addressing the pipeline gap and bringing innovative solutions to patients.
• Rising Awareness and Surveillance Programs: Enhanced global awareness campaigns and the implementation of robust surveillance programs are crucial drivers for the antimicrobial resistance market. The World Health Organization (WHO) has been instrumental in advocating for global action on AMR through initiatives like World Antimicrobial Awareness Week, which educates the public and healthcare professionals on the prudent use of antimicrobials. Furthermore, national and international surveillance systems, such as the European Centre for Disease Prevention and Control’s (ECDC) European Antimicrobial Resistance Surveillance Network (EARS-Net) and the CDC’s National Healthcare Safety Network (NHSN), provide critical data on resistance patterns. This data is vital for guiding treatment decisions, informing public health policies, and stimulating the development of targeted diagnostics and therapeutics. Increased awareness also fosters better infection prevention and control practices, further driving the need for effective AMR management.
• Governmental and Regulatory Support: Strong governmental and regulatory support through favorable policies and incentives is a significant catalyst for the antimicrobial resistance market. The U.S. Food and Drug Administration (FDA) has implemented various pathways, such as the Qualified Infectious Disease Product (QIDP) designation, to expedite the development and review of new antibacterial and antifungal drugs. This designation provides incentives like Fast Track and Priority Review, as well as an additional five years of market exclusivity. Similarly, the European Medicines Agency (EMA) offers scientific advice and accelerated assessment procedures for medicines addressing unmet medical needs, including those for antimicrobial resistance. These regulatory frameworks reduce the development risks and improve the commercial viability of novel antimicrobial agents, thereby encouraging pharmaceutical companies to invest in this challenging therapeutic area and bring much-needed innovations to market.

Antimicrobial Resistance Market Opportunities

• Development of Novel Antimicrobial Agents: The urgent global need for new classes of antibiotics and alternative antimicrobial therapies presents a significant market opportunity. With conventional antibiotics facing increasing resistance, the development of drugs with novel mechanisms of action is paramount. According to the World Health Organization, the clinical pipeline for new antibiotics remains insufficient to tackle the growing threat of antimicrobial resistance, with very few truly novel agents. This gap highlights a substantial opportunity for companies investing in groundbreaking research, including exploring bacteriophages, antimicrobial peptides, and gene-editing technologies. The promise of these innovative approaches lies in their potential to circumvent existing resistance mechanisms, offering effective treatments for multi-drug resistant infections that currently have limited therapeutic options.
• Investment in Rapid Diagnostics: The ability to quickly and accurately identify pathogens and their resistance profiles is a critical market opportunity. Rapid diagnostic tests can significantly improve patient outcomes by enabling timely and targeted antibiotic treatment, thereby reducing the overuse of broad-spectrum antibiotics and slowing the development of resistance. The Centers for Disease Control and Prevention emphasizes that rapid diagnostics are a key component of antibiotic stewardship programs, helping clinicians make informed decisions. Opportunities exist in developing point-of-care diagnostics, molecular tests, and other advanced technologies that can identify resistant strains within hours rather than days. This not only benefits individual patient care but also aids in public health surveillance by providing real-time data on resistance patterns, thereby guiding appropriate public health interventions.
• Emergence of Combination Therapies: The development of combination therapies, involving existing or new antimicrobial agents with resistance-modifying compounds, represents a promising market opportunity. These combinations aim to restore the efficacy of older antibiotics or prevent the emergence of resistance to new ones. The National Institutes of Health has supported research into combination therapies, recognizing their potential to overcome resistance mechanisms. For instance, combining a beta-lactamase inhibitor with a beta-lactam antibiotic can overcome resistance mediated by bacterial enzymes. This approach offers a way to extend the lifespan of existing antimicrobial drugs and provides more robust treatment options for complex infections. The market can capitalize on research into synergistic drug combinations and the development of fixed-dose combination products that simplify administration and improve patient adherence.
• Strategic Partnerships and Collaborations: Fostering strategic partnerships and collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and government bodies offers a substantial market opportunity. Such collaborations can pool resources, share expertise, and accelerate the discovery and development of new antimicrobial solutions. The Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit organization, exemplifies successful public-private partnerships aimed at developing new treatments for drug-resistant infections. These alliances can facilitate risk-sharing, optimize research pipelines, and ensure that promising candidates advance through clinical trials. Furthermore, collaborations can bridge the translational gap between basic scientific discoveries and their clinical application, addressing the significant challenges inherent in antimicrobial drug development and bringing much-needed innovation to the market.

Antimicrobial Resistance Market Restrain & Challenges

• High Cost of Research and Development: The development of new antimicrobial agents is characterized by exceptionally high research and development costs, posing a significant restraint on market growth. The complexity of discovering novel mechanisms of action, coupled with the rigorous regulatory requirements for clinical trials, translates into substantial financial investment. According to the U.S. Department of Health and Human Services, the estimated cost to bring a new drug to market can be in the hundreds of millions, if not billions, of dollars, with a high attrition rate at various stages of development. This financial burden often discourages smaller biotechnology firms and even larger pharmaceutical companies from investing heavily in this area, particularly given the relatively low return on investment compared to other therapeutic areas due to the limited duration of use for antibiotics.
• Regulatory Hurdles and Lengthy Approval Processes: Navigating the complex and often lengthy regulatory approval processes presents a significant challenge for the antimicrobial resistance market. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require extensive data on safety and efficacy, often necessitating large-scale and costly clinical trials. The unique nature of antimicrobial development, including the need to demonstrate superiority or non-inferiority against existing treatments and address specific resistant populations, can prolong the approval timeline. The World Health Organization has also highlighted the need for more streamlined regulatory pathways globally to accelerate the availability of new antimicrobials. These delays can significantly impact the commercial viability of new drugs and discourage investment, as companies face prolonged periods of expenditure without revenue generation.
• Limited Commercial Incentives and Return on Investment: The economic model for antimicrobial development often presents a significant challenge due to limited commercial incentives and a perceived low return on investment. Unlike chronic medications that are taken for extended periods, antibiotics are typically used for short durations, leading to lower sales volumes. This, combined with the pressure to conserve new antibiotics to mitigate the development of resistance, further restricts market potential. The U.S. Centers for Disease Control and Prevention emphasizes the importance of antibiotic stewardship, which, while crucial for public health, can paradoxically disincentivize commercial investment. Without innovative market entry and reimbursement models that recognize the public health value of new antimicrobials, companies may continue to prioritize other therapeutic areas with more predictable and higher financial returns.
• Emergence of New Resistance Mechanisms: The continuous evolution of bacteria and the emergence of new resistance mechanisms present an ongoing and formidable challenge for the antimicrobial resistance market. Microorganisms rapidly develop strategies to evade the effects of existing antibiotics, often through genetic mutations or the acquisition of resistance genes. The World Health Organization consistently reports on the emergence of novel resistance patterns, such as carbapenem-resistant Enterobacteriaceae (CRE) and colistin-resistant bacteria, which severely limit treatment options. This necessitates a constant race to discover and develop new drugs that can overcome these evolving threats. The dynamic nature of bacterial resistance means that even newly approved drugs can quickly face efficacy challenges, creating a perpetual need for innovation and rendering some investments obsolete in a relatively short timeframe.

Current Trends in the Antimicrobial Resistance Market

• Focus on Non-Traditional Antimicrobial Approaches: A significant trend in the antimicrobial resistance market is the increasing focus on non-traditional antimicrobial approaches beyond conventional small-molecule antibiotics. This includes exploring bacteriophages, which are viruses that specifically target and kill bacteria, as highlighted by the National Institutes of Health which has funded research into their therapeutic potential. Other areas of interest include antimicrobial peptides, which are naturally occurring molecules with broad-spectrum activity, and novel immunotherapies aimed at boosting the host's immune response against infections. This diversification of research efforts is driven by the urgent need to circumvent existing resistance mechanisms and develop therapies that are less prone to the rapid emergence of resistance, thereby offering more sustainable solutions for combating resistant infections.
• Integration of Artificial Intelligence and Machine Learning: The integration of artificial intelligence (AI) and machine learning (ML) is an emerging trend revolutionizing drug discovery and development in the antimicrobial resistance market. These technologies can rapidly analyze vast datasets, identify potential drug candidates, and predict their efficacy and toxicity profiles, thereby accelerating the R&D process. The U.S. Department of Health and Human Services has acknowledged the potential of AI in identifying novel antimicrobial compounds and optimizing drug design. AI algorithms can also be used to predict resistance patterns, aiding in the development of targeted diagnostics and personalized treatment strategies. This trend promises to significantly reduce the time and cost associated with bringing new antimicrobial agents to market, offering a more efficient pathway to address the pressing challenge of resistance.
• Emphasis on Global Collaboration and Data Sharing: There is a growing emphasis on global collaboration and data sharing among researchers, healthcare providers, and public health organizations to combat antimicrobial resistance more effectively. Initiatives like the Global Antimicrobial Resistance Surveillance System (GLASS) by the World Health Organization facilitate the collection and sharing of standardized data on resistance patterns from various countries. This collaborative approach enables better understanding of the global epidemiology of AMR, identifies emerging threats, and informs coordinated public health interventions. Such partnerships also facilitate the sharing of research findings, resources, and expertise, accelerating the discovery and development of new antimicrobials and diagnostics. This trend towards interconnectedness is vital for mounting a unified and effective response to a challenge that transcends national borders.
• Development of Rapid Diagnostic Technologies: The rapid development and adoption of advanced diagnostic technologies are a key trend in the antimicrobial resistance market. These technologies aim to quickly identify specific pathogens and their resistance mechanisms, enabling clinicians to prescribe targeted therapies from the outset. The Centers for Disease Control and Prevention advocates for rapid diagnostics as a cornerstone of antibiotic stewardship, as they help minimize the use of broad-spectrum antibiotics and improve patient outcomes. This includes molecular diagnostics, point-of-care tests, and next-generation sequencing, which can provide actionable information within hours rather than days. The increasing sophistication of these diagnostic tools is crucial for guiding appropriate treatment decisions, monitoring the spread of resistant strains, and supporting effective infection prevention and control strategies.

Segmentation Insights

Antimicrobial Resistance Market Analysis, By Indication

By indication, the market is divided into Complicated Urinary Tract Infections (cUTI), Blood Stream Infections, Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP and VABP), Community Acquired Pneumonia (CAP), and Others.

• The largest segment in the indication analysis is Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP and VABP). This segment leads due to the inherent vulnerability of hospitalized patients, particularly those on mechanical ventilation, to acquiring severe bacterial infections that are often multi-drug resistant. These infections are a major cause of morbidity and mortality in healthcare settings, leading to prolonged hospital stays and increased healthcare costs. The presence of compromised immune systems, invasive medical devices, and frequent exposure to antibiotic-resistant pathogens within the hospital environment contributes significantly to the prevalence and severity of HABP and VABP, driving the demand for effective antimicrobial treatments in this patient population.
• The fastest-growing segment within the indication analysis is Blood Stream Infections. This segment is experiencing rapid growth primarily due to the increasing incidence of bacteremia, often linked to the rise of healthcare-associated infections and the growing number of immunocompromised individuals. Bloodstream infections can quickly lead to sepsis and septic shock, conditions with high mortality rates, necessitating immediate and effective antimicrobial intervention. The challenges in treating these infections are further amplified by the increasing prevalence of multi-drug resistant pathogens circulating in the bloodstream, driving an urgent need for novel and potent antimicrobial agents. The critical nature and rapid progression of bloodstream infections contribute to the accelerated demand for solutions, making it a rapidly expanding segment.

Antimicrobial Resistance Market Analysis, By Drug Class

By Drug Class, the market is categorized into Combination Therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, and Others.

• The largest segment in the drug class analysis is Combination Therapies. This segment holds a leading position due to the increasing prevalence of multi-drug resistant infections that often require the synergistic action of multiple antimicrobial agents to achieve effective treatment. Combination therapies are frequently employed to broaden the spectrum of coverage, overcome existing resistance mechanisms, and reduce the likelihood of resistance development to a single agent. The complexity of treating severe infections, particularly those caused by extensively drug-resistant bacteria, often necessitates the use of a combination of drugs to maximize therapeutic efficacy and improve patient outcomes, thus driving significant demand within this segment.
• The fastest-growing segment within the drug class analysis is Oxazolidinones. This segment is experiencing rapid growth due to the increasing clinical utility of oxazolidinones in treating infections caused by Gram-positive bacteria, particularly those that are resistant to other common antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). As resistance to traditional antibiotics continues to spread, oxazolidinones provide a crucial therapeutic option for these challenging pathogens. Their distinct mechanism of action, which inhibits bacterial protein synthesis, contributes to their effectiveness against resistant strains, leading to their accelerated adoption and expansion in clinical practice.

Antimicrobial Resistance Market Analysis, By Mechanism of Action

By Mechanism of Action, the market is categorized into Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, and Others.

• The largest segment in the mechanism of action analysis is Cell Wall Synthesis Inhibitors. This segment leads due to the historical and continued widespread use of antibiotics that target bacterial cell wall synthesis, such as beta-lactams and glycopeptides, which are foundational treatments for a vast array of bacterial infections. Despite the emergence of resistance, these drug classes remain crucial in clinical practice due to their broad spectrum of activity and proven efficacy against many common pathogens. The continuous development of new derivatives and combinations within this class also contributes to its sustained dominance, providing solutions for infections where other mechanisms may be less effective.
• The fastest-growing segment within the mechanism of action analysis is Protein Synthesis Inhibitors. This segment is experiencing rapid growth due to of the increasing focus on developing new antibiotics that target bacterial protein synthesis, especially as resistance to other antibiotic classes becomes more widespread. The distinct mechanism of action of these inhibitors makes them effective against a range of resistant bacteria, including difficult-to-treat Gram-positive pathogens. The urgent need for novel therapies that can overcome existing resistance mechanisms drives significant research and development efforts in this area, leading to the accelerated introduction of new drugs within this class that offer effective solutions for a growing number of resistant infections.

Antimicrobial Resistance Market Analysis, By Pathogen

By Pathogen, the market is categorized into Klebsiella Pneumoniae, Pseudomonas Aeruginosa, Staphylococcus Aureus, Enterococcus spp, Escherichia Coli, and Others.

• The largest segment in the pathogen analysis is Staphylococcus Aureus. This segment leads due to the widespread prevalence of Staphylococcus Aureus infections, particularly methicillin-resistant Staphylococcus aureus (MRSA), which poses a significant public health threat in both healthcare and community settings. Staphylococcus Aureus can cause a diverse range of infections, from skin and soft tissue infections to life-threatening conditions like endocarditis and bloodstream infections. The bacterium's ability to develop resistance to multiple antibiotics, including those of last resort, continuously drives the demand for novel and effective antimicrobial agents specifically targeting this prevalent and adaptable pathogen.
• The fastest-growing segment within the pathogen analysis is Pseudomonas Aeruginosa. This segment is experiencing rapid growth due to the increasing incidence of multi-drug resistant Pseudomonas Aeruginosa infections, particularly in hospitalized and immunocompromised patients. Pseudomonas Aeruginosa is notorious for its intrinsic resistance mechanisms and its ability to acquire further resistance, making infections incredibly challenging to treat. It is a common cause of ventilator-associated pneumonia, bloodstream infections, and infections in burn patients. The urgent clinical need for new therapeutic options to combat these highly resistant strains, coupled with the high morbidity and mortality associated with these infections, is accelerating the development and adoption of novel treatments specifically targeting Pseudomonas Aeruginosa.

Antimicrobial Resistance Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• The largest region in the Antimicrobial Resistance market is North America. This region leads due to its well-established healthcare infrastructure, high healthcare expenditure, significant research and development investments, and the presence of numerous key pharmaceutical and biotechnology companies. Robust government funding for antimicrobial resistance initiatives, coupled with a strong regulatory framework that encourages innovation, also contributes to its dominance. Furthermore, the high awareness of antimicrobial resistance among healthcare professionals and the public, along with the prevalence of advanced diagnostic capabilities, drives the demand for novel antimicrobial agents and solutions in this region, making it a primary hub for market activity and innovation.
• The fastest-growing region within the Antimicrobial Resistance market is Asia-Pacific. This region is experiencing rapid growth primarily due to its large and increasing population, coupled with improving healthcare infrastructure and rising healthcare expenditure. The high burden of infectious diseases and the growing prevalence of antimicrobial resistance in countries across Asia-Pacific are creating a significant unmet need for effective treatments and diagnostics. Furthermore, increasing government initiatives to combat AMR, growing awareness, and the presence of emerging economies with expanding pharmaceutical sectors are contributing to the accelerated adoption of new antimicrobial solutions, positioning Asia-Pacific as a dynamic and rapidly expanding market for antimicrobial resistance products.

Antimicrobial Resistance Market Competitive Overview

The competitive landscape of the Antimicrobial Resistance market is characterized by a mix of established pharmaceutical giants and emerging biotechnology companies actively engaged in the discovery, development, and commercialization of novel antimicrobial agents and diagnostics. Companies are primarily focused on addressing the critical unmet need for effective treatments against drug-resistant pathogens, often through strategic collaborations and partnerships to accelerate research and development. The market is dynamic, with ongoing innovation in areas such as new antibiotic classes, bacteriophage therapy, and advanced diagnostic tools. Competition intensifies as companies strive to overcome the challenges associated with the high cost of R&D and the unique regulatory pathways for antimicrobial drugs. The competitive environment also sees players emphasizing portfolio expansion through licensing agreements and acquisitions to strengthen their market position and address the global threat of antimicrobial resistance.

Leading Market Players in the Antimicrobial Resistance Market

• Merck & Co., Inc.: Merck & Co., Inc. is a prominent pharmaceutical company with a significant presence in the antimicrobial resistance market. The company has a diverse portfolio of anti-infective products and a robust pipeline focused on addressing challenging bacterial and fungal infections. Their long-standing commitment to infectious diseases research underscores their dedication to combating the global threat of antimicrobial resistance. Merck's efforts involve both the development of novel antibiotics and the enhancement of existing therapies to maintain efficacy against evolving resistant pathogens. The company also engages in strategic partnerships and collaborations to accelerate the discovery and development of innovative solutions, reflecting its comprehensive approach to tackling antimicrobial resistance challenges.
• Pfizer Inc.: Pfizer Inc. is a leading global pharmaceutical company with a substantial footprint in the antimicrobial resistance market. The company possesses a broad portfolio of anti-infective medicines, including several key antibiotics used to treat a wide range of bacterial infections. Pfizer is actively engaged in research and development initiatives aimed at discovering and advancing new antimicrobial agents to address the growing challenge of drug resistance. Their commitment extends to developing treatments for difficult-to-treat infections and participating in global efforts to promote antibiotic stewardship. Pfizer’s extensive research capabilities and global reach position it as a significant contributor to the ongoing fight against antimicrobial resistance.
• Wockhardt Limited.: Wockhardt Limited is an Indian pharmaceutical and biotechnology organization that has made notable contributions to the antimicrobial resistance market. The company is recognized for its focus on discovering and developing novel antibiotics to combat multi-drug resistant pathogens. Wockhardt has a dedicated research program aimed at addressing the critical unmet medical need for new anti-infective solutions. Their efforts include developing new chemical entities with unique mechanisms of action, providing crucial therapeutic options for infections that are increasingly difficult to treat with existing drugs. Wockhardt's commitment to innovation in the anti-infective space underscores its role in the global fight against antimicrobial resistance.

Top Strategies Followed by Players

• Strategic Alliances and Collaborations: A prominent strategy employed by players in the Antimicrobial Resistance market is the formation of strategic alliances and collaborations. Companies are increasingly partnering with academic institutions, biotechnology firms, and government agencies to share expertise, pool resources, and accelerate the discovery and development of new antimicrobial agents. For instance, according to the U.S. Centers for Disease Control and Prevention, public-private partnerships are crucial in developing new diagnostic tools and treatments for antibiotic-resistant infections. These collaborations allow for risk-sharing in the high-cost and high-risk endeavor of antibiotic research and development, enabling companies to leverage diverse scientific perspectives and technologies. This approach helps to overcome financial hurdles and expedite the translation of scientific discoveries into clinically viable solutions, ultimately broadening the pipeline of much-needed antimicrobial therapies.
• Focus on Novel Mechanism of Action Drugs: Companies are prioritizing the development of drugs with novel mechanisms of action to overcome existing resistance mechanisms and provide effective treatments against multi-drug resistant pathogens. The World Health Organization consistently highlights the critical need for new classes of antibiotics, as the pipeline of truly novel agents remains insufficient. This strategic focus involves extensive research into new molecular targets within bacteria, exploring unconventional approaches such as bacteriophages, and developing resistance-modifying compounds that can restore the efficacy of older antibiotics. By innovating beyond existing drug classes, companies aim to create therapies that are less prone to rapid resistance development, thereby offering more sustainable solutions for the escalating global threat of antimicrobial resistance.
• Investment in Research and Development: Significant investment in research and development (R&D) is a cornerstone strategy for players in the Antimicrobial Resistance market. This involves substantial financial commitments to drug discovery, preclinical testing, and clinical trials to identify and validate new antimicrobial compounds. According to data from the U.S. Department of Health and Human Services, funding for antimicrobial resistance research has seen sustained support from government agencies, reflecting the urgency of the issue. Companies are establishing dedicated R&D centers and recruiting top scientific talent to advance their pipelines. This continuous investment is critical for addressing the scientific complexities of antimicrobial resistance, such as the rapid evolution of bacterial resistance, and for navigating the stringent regulatory pathways required to bring innovative anti-infective solutions to market.

List of Companies Profiled in the Report are:

• Alkem Laboratories Ltd.
• Acurx Pharmaceuticals Inc.
• Merck & Co. Inc.
• Cumberland Pharmaceuticals
• Wockhardt Limited.
• Pfizer Inc.
• Nabriva Therapeutics plc
• Innoviva Inc
• Basilea Pharmaceutica Ltd
• Paratek Pharmaceuticals Inc

Global Antimicrobial Resistance Market Report: Scope

List of Segments Covered

This section of the Antimicrobial Resistance market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

• Complicated Urinary Tract Infections (cUTI)
• Blood Stream Infections
• Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
• Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP and VABP)
• Community Acquired Pneumonia (CAP)
• Others

By Drug Class

• Combination Therapies
• Tetracyclines
• Cephalosporins
• Glycopeptides and Lipoglycopeptides
• Oxazolidinones
• Others

By Mechanism of Action

• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• Others

By Pathogen

• Klebsiella Pneumoniae
• Pseudomonas Aeruginosa
• Staphylococcus Aureus
• Enterococcus spp
• Escherichia Coli
• Others